Objective: To explore the relationship between the expression of cyclic RNA(CircRNA) adisintegrin and metalloproteinases 22(ADAM22) in non-small cell lung cancer(NSCLC) tissues and the sensitivity of cisplatin containing chemotherapy regimens. Methods: 103 NSCLC patients who received treatment in our hospital from February 2018 to February 2020 were selected as the study subjects, all of whom received cisplatin containing chemotherapy regimens. The expression of CircRNA ADAM22 in lung cancer tissues and adjacent tissues were detected by using real time fluorescence quantitative polymerase chain reaction. The relationship between the expression of CircRNA ADAM22 in lung cancer tissues and the clinicopathological characteristics of patients was analyzed. According to the recent efficacy of chemotherapy, patients were divided into chemotherapy effective group and chemotherapy ineffective group, and the expression of CircRNA ADAM22 in lung cancer tissues was compared between the two groups. The relationship between CircRNA ADAM22 expression in lung cancer tissues and chemotherapy sensitivity was analyzed by using Logistic regression model. The risk factors affecting patient survival was analyzed by using Cox proportional risk regression model. The relationship between the expression of CircRNA ADAM22 in lung cancer tissues and the 3-year survival rate of patients was analyzed by using Kaplan-Meier method. Results: The expression level of CircRNA ADAM22 in lung cancer tissues(2.69±0.65) was higher than that in adjacent tissues(1.47±0.36)(P<0.05). There was no statistically significant difference in the expression of CircRNA ADAM22 in lung cancer tissues between patients of different genders, ages, histological types, degrees of differentiation and smoking history(P>0.05), but the proportions of high expression of CircRNA ADAM22 in lung cancer tissues of patients with tumor node metastasis(TNM) stage Ⅲ+Ⅳ and lymph node metastasis were higher than patients with TNM stage Ⅱ and no lymph node metastasis(P<0.05). The proportion of high expression of CircRNA ADAM22 in cancers tissues in the chemotherapy ineffective group was higher than that in the chemotherapy effective group(P<0.05). Multivariate Logistic regression analysis showed that TNM stage Ⅲ+Ⅳ, lymph node metastasis, high expression of CircRNA ADAM22 in lung cancer tissues and no combined use of immunosuppressants were all risk factors affecting the sensitivity of cisplatin containing chemotherapy regimens in NSCLC patients(P<0.05). The 3-year survival rate of 103 NSCLC patients was 55.34%. The proportion of high expression of CircRNA ADAM22 in cancer tissues in dead patients was higher than that in survivors(P<0.05). Multivariate Cox proportional risk regression model analysis showed that lymph node metastasis, high expression of CircRNA ADAM22 in cancer tissues and no combined use of immunosuppressants were risk factors for 3-year mortality in NSCLC patients(P<0.05). According to Kaplan-Meier survival curve analysis, the 3-year survival rate of patients with high expression of CircRNA ADAM22 in lung cancer tissues was lower than patients with low expression of CircRNA ADAM22 in cancer tissue(P<0.05). Conclusion: The expression of CircRNA ADAM22 in NSCLC tissues is high, and its high expression is closely related to the sensitivity of cisplatin containing chemotherapy regimens and survival of patients, and it can be used as a biological indicator for clinical prediction of the efficacy of cisplatin containing chemotherapy regimens and survival in NSCLC patients.